Background Daylight PDT (dPDT) is an effective and nearly painless treatment for field-change actinic keratosis. Measuring the protoporphyrin-IX (PpIX)-weighted exposure dose can give an indication of when conditions are most viable for effective dPDT. It would be advantageous for practitioners if more detailed information of exposure dose and appropriate treatment conditions were available. Where sophisticated measurement equipment is unavailable, simpler and more cost-effective methods of dose measurement are desirable.
• Detailed objective information from nine locations across the U.K. and Ireland with respect to possible treatment conditions for dPDT.
• Increased understanding and confidence in the exposure conditions for effective dPDT in the U.K.
Photodynamic therapy (PDT) is an attractive treatment for superficial nonmelanoma skin cancers and dysplasia, including actinic keratosis (AK). Conventional PDT (cPDT) can be performed over a relatively large surface area (up to approximately 5 9 10 cm 2 ), 1 with high efficacy, good cosmetic outcome and high patient satisfaction. [2] [3] [4] [5] In cPDT, light is delivered to the target area, typically using a bank of red light-emitting diodes. 1 The dose of light delivered to the skin surface is the product of the irradiance at the skin surface and the exposure time. Sufficient photobleaching of the photosensitizer, protoporphyrin-IX (PpIX), is required for effective treatment. Both irradiance and time are easily controlled in cPDT, which allows for accurate determination of the delivered light dose. However a disadvantage of this treatment is that it can be painful, [6] [7] [8] and requires multiple visits to hospitals for patients with extensive field-change, requiring large area treatment.
A less painful and more efficient alternative to cPDT for the treatment of field-change AK is daylight PDT (dPDT), where the sun is used as the light source for treatment. 6, 9, 10 The sun is a broadband source containing ultraviolet, visible and infrared electromagnetic radiation, which targets all of the absorption peaks of PpIX. dPDT treatment times are longer than those for cPDT, with an international consensus recommending at least 2 h of daylight exposure for effective treatment.
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This exposure time can be controlled; however, the irradiance of daylight at the treatment site is somewhat harder to predict, particularly in locations with variable weather conditions, such as the U.K. This makes accurate dosimetry of dPDT more challenging in contrast to cPDT, and is a limiting factor for physicians and patients as there is a degree of uncertainty and thus lack of confidence in treatment. Previous studies have measured the light dose during dPDT with differing methodologies, including (i) the use of a specialized device worn on the wrist to measure directly the PpIX-weighted light dose; 10 (ii) spectroradiometers to measure daylight spectral irradiance; 12 and (iii) handheld light meters. 9 These techniques require expensive and often bespoke equipment with associated support from a metrology specialist such as a medical physicist, while one of the advantages of dPDT itself is that it is a relatively simple treatment that does not require high specialist input. If the dosimetry associated with dPDT could be simplified so that it is cheap and simple to perform, the treatment may be more attractive, where practitioners want the reassurance of accurate dosimetry but do not have the specialist support to perform some of the previously mentioned techniques. This would be particularly important in countries such as the U.K., where weather conditions and light levels can vary dramatically during a day.
As a solution, we propose that illuminance, as measured in lux, can be used in a simple calculation to determine the effective PpIX-weighted irradiance, and subsequently the PpIX-weighted exposure dose. To validate this model, we compared the modelling results with direct spectral irradiance measurements made at three sites across the U.K. Following validation, historical illuminance and temperature data from nine sites across the U.K. were analysed, and could then be used to recommend appropriate times of the year and days for performing dPDT. This could facilitate more informed clinical practice, and provide information for centres considering dPDT as a treatment option.
Materials and methods

Conversion model
Data collection
Over 6000 spectral irradiance measurements of daylight were obtained from Public Health England's monitoring station in Chilton, U.K. (51Á575°N, 1Á318°W), in 15-min intervals between the hours of 09:00 and 17:00, from March to October 2015. The measurements were made in the horizontal plane using a Glacier X TE-cooled charge-coupled device array spectroradiometer (BWTek, Newark, NJ, U.S.A.), coupled to a D7-SMA diffuser (Bentham Instruments, Reading, U.K.) by optical fibre. The instrument was calibrated in an environmentally controlled laboratory using 1000-W tungsten-halogen lamps, calibrated for spectral irradiance to the PhysikalischTechnische Bundesanstalt traceable reference standards (Braunschweig und Berlin, https://www.ptb.de). Full-day data were excluded if there were missing time points during the day, and time points were excluded if they occurred after sunset.
Model
Illuminance and PpIX-weighted irradiance were obtained from the product of the spectral irradiance data and the luminosity and PpIX absorption function, respectively. 13, 14 A ratio of PpIX-weighted irradiance to illuminance for each data point was determined and an iterative process was undertaken to produce a model that accurately converted illuminance to PpIX-weighted irradiance. At each stage in the iterative process, results from the current model were compared with the values of PpIX-weighted irradiance derived from the measurements.
Model verification
To test the developed model, daylight spectral irradiance data (acquired similarly to the Chilton monitoring station) from three U.K. sites -Salisbury (51Á07°N, 1Á79°W), Nottingham (53Á07°N, 1Á24°W) and Dundee (54Á46°N, 2Á97°W) -were obtained; the model was applied to the data and the percentage difference in actual and calculated PpIX-weighted irradiances calculated. This was used as a metric to evaluate the conversion model in different locations.
Statistical analysis
Statistical analysis was performed in JMP, using bivariate analysis or ANOVA where appropriate. Significance was set at P < 0Á01.
U.K. location analysis
Public Health England operates a solar monitoring network at nine locations in the U.K. and Ireland (Fig. 1) ; 15 illuminance is recorded using Macam Photometrics SD-104 Lcos detectors. Over 500 000 measurement data points were obtained at 5-min intervals between 09:00 and 17:00 from 1 January to 31 December in 2013-15 inclusive. A custom-written MATLAB program, using the model previously described, was used to convert the illuminance values to PpIX-weighted irradiance and subsequently PpIX-weighted exposure dose. In addition, temperature data (data accessed from Weather Underground) 16 for each location were obtained over the same period as the illuminance data. The mean daily maximal temperature and effective dose data were used to recommend months and times of the day for each location when daylight PDT could be performed. When setting the minimum criteria required for effective daylight PDT, a temperature of 10°C and a dose of 4 J cm
À2
were used, based upon recent published literature. 12, 17, 18 A treatment time of 2 h was assumed.
The predicted months and times of day were also calculated for conservatory dPDT, assuming no dependence on outside temperature and a reduction in the incoming daylight by 25%. 19 Figure 2 shows the PpIX-weighted-irradiance-to-illuminance ratio as a function of the illuminance. Lower illuminance values are associated with higher ratios. As a first iteration, a logarithmic equation [Equation (1)] is fitted to the data (R 2 = 0.3399).
Results
Model
where E v is the illuminance. The calculated PpIX-weighted irradiance [Equation (1) multiplied by the illuminance] has a mean AE SD difference of 0Á53 AE 7Á85% when compared with the true PpIX-weighted irradiance. However, there is a dependence of the percentage error on time of day (P < 0Á01) and year (P < 0Á01), with Equation (1) undercompensating around solar noon and overcompensating at the start and end of the day.
The elevation angle of the sun (position of the sun in the sky) and the declination angle of Earth (tilt of Earth relative to the sun; data provided by NOAA ESRL Global Monitoring Division, Boulder, CO, U.S.A.) 20 are used to correct for these trends [Equation (2)]:
where E e is the PpIX-weighted irradiance (mW m À2 ), and E v , Φ e , Φ e(max) and Φ d are the illuminance (lux), solar elevation angle, maximum solar elevation angle in the year and declination angle, respectively. Using Equation (2), the mean AE SD percentage difference between the calculated and the actual values is 0Á04 AE 6Á80%, and the percentage error is independent of time of day or time of year. 
Model verification
The model has been verified, resulting in a good agreement against spectral irradiance data from Salisbury, Nottingham and Dundee. Figure 3 shows the percentage difference between the calculated PpIX-weighted irradiance and the true PpIX-weighted irradiance at three locations. The mean AE SD differences are 1Á76% AE 8Á01%, -4Á13% AE 3Á95% and 2Á19% AE 4Á88% against the Nottingham, Salisbury and Dundee data, respectively.
U.K. location analysis
Using the developed model, historic illuminance data from nine sites around the U.K. were analysed in order to present the expected mean PpIX-weighted exposure doses in each location throughout the year. Figure 4 displays the mean dose for each month over the 3-year period 2013-2015 at each location. The mean daily maximal temperatures for each location are shown in Figure 5 .
Analysis of the most appropriate treatment times of the day, following the aforementioned criteria (PpIX dose > 4 J cm À2 and ambient temperature > 10°C), is given in Table 1 , with full data displayed in Figure 6 . Table 2 details when treatment would be possible in a conservatory -the temperature restriction of 10°C has been removed and the dose data have been reduced by 25% to take account of the attenuation by glass.
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Discussion dPDT is increasingly used and has a strong evidence base to support its application in Europe and Australia. 6, 21 However, the use of dPDT has somewhat lagged behind in the U.K., although several centres commenced this treatment modality within the last year. There is understandable concern about the use of a treatment in the U.K. that relies on the weather, and guidance and confidence in the use of effective light delivery is required. The model presented here can be used to calculate accurately the PpIX-weighted exposure dose during dPDT using only the measured illuminance, and the time and date, duration and location of treatment to provide confidence to presubscribers of dPDT. The model first takes the illuminance reading and converts this reading in to PpIX-weighted irradiance -this is done by first accounting for the logarithmic trend of the conversion factor shown in Figure 2 , and by correcting for the elevation angle, which is specific to the location of measurement, and the declination angle, which is specific to the time of measurement. This process produces a corrected, accurate PpIX-weighted irradiance value, which can then be multiplied by the time of exposure to output the PpIX-weighted exposure dose.
Illuminance can be measured using inexpensive luxmeters, which makes this an attractive option in clinics where more advanced dosimetry techniques are not available. The developed model shows good accuracy in different locations (Fig. 3) , which adds further confidence to the robustness of the model. This method accounts for different weather conditions, which are factored in to the error margins presented.
Deciding on the suitable months to use dPDT in different geographical locations primarily depends on the minimum The data show accuracies of 1Á76% AE 8Á01%, -4Á13% AE 3Á95% and 2Á19% AE 4Á88% for the Nottingham, Salisbury and Dundee data, respectively. This means, e.g., in Dundee the model predicts the PpIX-weighted exposure dose is, on average, 2Á19% higher than the true value. These results show the expected mean + SD protoporphyrin-IX (PpIX)-weighted exposure dose at each of the nine locations for a 2-h daytime photodynamic therapy (dPDT) treatment. In general, months where the expected PpIX-weighted exposure dose is < 4 J cm À2 should not be recommended for dPDT. The values do not discriminate for weather conditions; therefore, on clearer days the PpIX-weighted exposure dose could be expected to be higher than the mean values presented.
PpIX-weighted exposure dose for effective treatment. There is a general consensus among several published studies, which state that above a certain value there is no significant increase in treatment efficacy; ergo, there exists a minimum dose for effective treatment. However, there is no firm consensus on what this minimum dose is for effective AK treatment, with values ranging from 3 to 16 J cm À2 . 9, 12, 17, 18, 22, 23 One study even found no correlation between effective dose and treatment efficacy for a range of 0Á2-28 J cm À2 . 10 Varying reports on minimum light doses for dPDT can potentially be explained by the different measurement systems used in these studies, and the different characteristics of patients and AK lesions treated. Thinner AK lesions respond better to dPDT than thicker lesions, although there is no evidence yet to suggest that higher doses of light exposure equate to improved treatment efficacy for any grade of lesion. 17 The difference in efficacies seen between different thicknesses of AK lesions is perhaps owing to the depth of penetration of the incident daylight. The peak PpIX absorption during dPDT is in the blue region of the electromagnetic spectrum, where penetration depth into the skin is relatively low compared with the red portion of the spectrum, where there is less absorption by PpIX but much increased tissue penetration. These recommendations are based on a 2-h exposure time. For the times of day presented, these represent the times in which treatment should take place, e.g. for Lerwick in May treatment should not start earlier than 09:00 and finish no later than 16:00. Shortest times to reach the minimum PpIX exposure dose in the months with the highest mean dose are included, i.e. on average, how long will it take to receive the minimum PpIX exposure dose in the corresponding month. These minimum times are indiscriminate of weather conditions. Therefore, it may be important to account for the nature of the lesion treated before assessing a minimum dose required. The 2012 study by Wiegell et al. indicated that combining analysis of all AK thicknesses could give a minimum dose whereby above a certain threshold there is no significant change in efficacy with further increasing light dose, whereas separating analysis of AK thicknesses gave no significant effects of light dose on efficacy between the individual grades of lesion. 17 Therefore, we analysed our data against a minimum PpIX-weighted light dose of 4 J cm À2 based on current best estimates from the literature, and while this dose is lower than the recommendations from the European Consensus guidelines, 11 it is based upon more extensive and up-to-date data from recent publications. 12, 17, 18 Using this value, the mean + SD PpIX-weighted dose each month for each location is shown in Figure 4 . From these data, Table 1 was constructed, showing the possible times of the year for treatment. It is worth noting that as these data encompass all weather conditions, it is likely that on clear days the expected dose would be towards or even above the 1 SD presented in Figure 4 .
Another important consideration is the ambient temperature. It is generally considered that it would not be comfortable for patients to remain outdoors in temperatures < 10°C . 11 For this reason, temperature data were included in this analysis. The data presented in Table 1 and Figure 6 show that suitable months for dPDT begin in March (London), April (Inverness, Glasgow, Malin Head, Belfast, Leeds, Swansea, Camborne) or May (Lerwick), and finish in October (Lerwick, Inverness, Glasgow and Belfast), November (Malin Head and Belfast) or December (Swansea, London and Camborne). We established that even though there may be a sufficiently high light dose in some months, the ambient temperature may be too low, becoming a limiting factor in recommending dPDT, in particular for the early months of the year. One must also consider weather conditions such as wind, where even though the ambient temperature may be above 10°C, it may feel too cold or uncomfortable for patients to remain outdoors for extended periods of time. Therefore, even with guidelines, recommendation of dPDT should remain at the discretion of the clinician and patient. The use of conservatories could facilitate dPDT when temperature or other weather conditions would otherwise hinder treatment if there is still enough daylight. To achieve an equivalent exposure dose to dPDT, the treatment time for conservatory-based dPDT should be increased by 33% to account for the attenuation of visible light through window glass. This would mean that, based on a recommended treatment time of 2 h for dPDT, conservatory-based dPDT treatment time should be recommended at 2 h and 40 min to maintain dose equivalence between the two methods. Studies suggest that low irradiance PDT with longer treatment times can still be as effective as conventional PDT. 19, 25, 26 A randomized, multicentre study found no statistical significance when comparing lesion response rate and adverse effects between patients who had dPDT for 1Á5-and 2Á5-h exposures. 10 This indicates that extending the time of exposure by 40 min for conservatorybased dPDT with a lower irradiance to maintain dose equivalence with dPDT should have little to no effect on lesion response rate or treatment tolerability. Table 2 gave the recommended months for conservatory dPDT. These data show that conservatory-based dPDT can be recommended earlier in the year, in January (Belfast, Leeds, Swansea, London and Camborne) or February (Lerwick, Inverness, Glasgow and Malin Head), while at the end of the year the months for viable treatment conclude in October (Lerwick and Glasgow), November (Inverness, Malin Head, Belfast and Leeds) and December (Swansea, London and Camborne). These data suggest that, for the south of the U.K. in particular, conservatory-based dPDT could be carried out for nearly the Table 2 Start and end treatment months and times of the day for conservatory-based daytime photodynamic therapy (dPDT) at each location, accounting for a 25% attenuation of daylight and negating any temperature effects These recommendations are based on a 2Á5-h exposure time. For the times of day presented, these represent the times in which treatment should take place, e.g. for Lerwick in February treatment should not start earlier than 09:00 and finish no later than 16:00. Shortest times to reach the minimum protoporphyrin-IX (PpIX) exposure dose in the months with the highest mean dose are included, i.e. on average, how long will it take to receive the minimum PpIX exposure dose in the corresponding month. These minimum times are indiscriminate of weather conditions.
whole calendar year -in contrast to standard dPDT -owing to the higher temperatures and reduced wind effects inside the conservatory. The times of day suitable for conservatorybased dPDT in the summer months will likely extend beyond the minimum time ranges presented in Table 2 . Tables 1 and 2 also give the time required to achieve the minimum PpIX exposure dose in the months with the highest mean dose. These data suggest that the minimum light dose can be reached in as little as 16Á1 min in the southerly locations. It is important to note that these presented times do not serve as a recommendation for treatment times, as there are currently no studies that suggest treatment times as low as these can provide effective dPDT. In fact, it is suggested that treatment times < 1 h may provide insufficient time for photosensitizer production. 27 However, these data can give confidence to practitioners of dPDT that interruptions in the patients' daylight exposure (e.g. patchy cloud cover or rain) may be tolerable provided the recommended treatment protocol is followed. The analysis of the most appropriate times of the day for dPDT showed suitability at the start and end months from 09:00 to either 16:00 or 17:00. Select time intervals in the 'unsuitable' months may also be appropriate for dPDT, for example around solar noon on clear days when there is the most daylight, even though the mean monthly dose itself is deemed too low for effective treatment. Again, temperatures and weather effects in these periods could limit treatment. Conservatory-based dPDT slightly narrows time ranges for achieving minimum PpIX-weighted dose, owing to the reduction in daylight.
The presented data provide confidence that dPDT can be performed throughout the U.K., from the most southerly to the most northerly locations, and that effective exposure doses can be achieved. Indeed, dPDT can be performed at times of the year in the U.K. not previously considered, particularly when a conservatory is used to combat low ambient temperatures. Illuminance measurements are simple to perform and the equipment required is not expensive. The model for estimating the expected PpIX-weighted exposure dose for dPDT in the U.K. has been developed based on spectral irradiance measurements, and verified against spectral irradiance data from other U.K. locations, with good agreement. It is anticipated that this model could help inform those involved in delivering dPDT clinical services, when combined with an inexpensive personal luxmeter, about patient-specific dose delivery during dPDT. Those considering dPDT may look to these results as a guide and to provide confidence without the need for conducting measurements themselves, or alternatively may carry out dosimetry using this presented method of determining PpIX-weighted exposure dose from a single measurement of illuminance.
